Loke et al show presence of TP53 mutations in acute myeloid leukemia (AML) are associated with an inferior outcome after an allogeneic stem cell transplant.

Authors find presence of posttransplant MRD has an adverse prognostic impact on the outcome irrespective of pretransplant MRD in patients with AML/MDS.

Authors use barcoded in vivo CRISPR-Cas9KO screen to identify Ncoa4 as a dependency in Tet2-mutant HSPCs and reveals a promising therapeutic target for early intervention.

Dr Luciano Nicosia has been awarded a 3-year Early Career Advancement Fellowship with Blood Cancer UK. 

With funding from Blood Cancer UK, Mark Willams and Robert Wynn are setting up a clinical trial that aims to transform stem cell transplantation and offer new hope for many young adults with AML.

Somerville et al. report frequent derepression of FOXC1 in human acute myeloid leukemia in association with the HOXA/B locus. FOXC1 contributes to monocyte lineage differentiation block and enhanced clonogenic potential and collaborates with HOXA9 to accelerate leukemia onset in vivo.

In this study, the authors investigated the molecular mechanisms controlling the generation of HSCs during the intra-embryonic wave of haematopoiesis in the AGM and demonstrate a prominent role for the transcriptional repressors GFI1 and GFI1B in this process.

Leukaemic fusion proteins drive leukaemia by maintaining abnormal transcriptional networks. This study demonstrates the feasibility of epigenomics-instructed screens for identifying oncogene-driven vulnerabilities and their exploitation by repurposed drug approaches.

The epigenetic factors KAT6A and KMT2A interact in normal hematopoiesis to regulate progenitors’ self-renewal. Authors evaluated the potential of different KAT6A therapeutic targeting strategies to alter the growth of KAT6A and KMT2A rearranged AMLs.